Monday, October 30, 2017
Zydus Cadila has received the final approval from the USFDA to market Tamoxifen Citrate Tablets USP in the strengths of 10 mg (base) and 20 mg (base). The drug is indicated to treat breast cancer in women and men and to reduce the incidence of breast cancer in women at high risk for breast cancer. It will be manufactured at the group’s formulations manufacturing facility at SEZ, Ahmedabad.
The group now has more than 165 approvals and has so far filed over 300 ANDAs since the commencement of the filing process in FY 2003-04.
